NCT07861191Recruiting
RESET-INSPIRE Study: Insulin Sensitivity & Population Intervention With Real-time Evaluation Using CGM
Source: ClinicalTrials.gov · Last updated 6 Oct 2026
Brief summary (registry, in English)
The RESET-INSPIRE study is designed to investigate individual variability in glucose response and insulin sensitivity, a key mechanism underlying metabolic-associated steatotic liver disease (MASLD) and cardiometabolic disorders. Building on findings from Project RESET, this study aims to develop and validate a continuous glucose monitoring (CGM)-based approach for assessing insulin sensitivity.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 270 (estimated)
- First submitted
- 25 Sept 2026
- Start date
- 27 Jul 2026
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- National University Health System, Singapore
- Diseases
- Fatty liver disease (MASLD/MASH)
- NCT number
- NCT07861191
What you commit to
- Study type: Observational
- Planned participants: 270
- From 27 Jul 2026 to the primary completion date, 31 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Known diagnosis of diabetes mellitus (type 1 or type 2), or use of antidiabetic medication.
- Known history of liver disease or abnormal liver function deemed clinically significant by the investigator who is a medical doctor.
- Known allergy or intolerance to CGM adhesives or inability to comply with CGM sensor placement, or
- Any medical, psychiatric, or social condition that, in the opinion of the investigator, would interfere with the participant's ability to adhere to study procedures or would pose additional risk.
Lab values
- Current or recent (within 3 months) use of medications known to affect glucose, including but not limited to corticosteroids.
- Renal impairment, defined as eGFR ≤ 60mL/min/1.73m\^2
Other
- Known pregnancy, plans to become pregnant during the study period, or currently breastfeeding, or
- Participation in another interventional clinical trial within the past 3 months.
Who the study is looking for
- Adults aged between 21 and 70 years (including 70 yrs old) at the time of screening
- Able to speak and understand English
- No past history of acute myocardial infarction (heart attack), stroke or heart failure
- Able to understand and voluntarily provide written informed consent prior to any study specific procedures.
- No current diagnosis of type 1 or type 2 diabetes, and not taking glucose-lowering medications.
- Willing and able to comply with all scheduled study procedures.
Age in the registry: 21 years to 70 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| MD6, Centre for Translational Medicine, 14 Medical Drive, Singapore 117599 Coordinator of this site? Confirm its status | Singapore | Singapore | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.